H P Hansen
Overview
Explore the profile of H P Hansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindhard K, Rix M, Heaf J, Hansen H, Pedersen B, Jensen B, et al.
BMC Nephrol
. 2021 Aug;
22(1):283.
PMID: 34419006
Background: An arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis treatment. After creation many of the AVFs will never mature or if functioning will need an intervention within...
2.
Sauer M, Schuldner M, Hoffmann N, Cetintas A, Reiners K, Shatnyeva O, et al.
Oncogene
. 2016 Aug;
36(7):933-941.
PMID: 27477692
Tumor surveillance of natural killer (NK) cells is mediated by the cytotoxicity receptor natural-killer group 2 member D (NKG2D). Ligands for NKG2D are generally not expressed on healthy cells, but...
3.
Schiffer S, Hansen H, Hehmann-Titt G, Huhn M, Fischer R, Barth S, et al.
Blood Cancer J
. 2013 Mar;
3:e106.
PMID: 23524591
Tumors develop when infiltrating immune cells contribute growth stimuli, and cancer cells are selected to survive within such a cytotoxic microenvironment. One possible immune-escape mechanism is the upregulation of PI-9...
4.
Andresdottir G, Bakker S, Hansen H, Parving H, Rossing P
Diabet Med
. 2013 Jan;
30(5):563-6.
PMID: 23324103
Aims: Hydrogen sulphide levels are reduced in many disease states, including diabetes and end-stage renal disease. We aimed to determine whether urinary sulphate excretion, as a proxy for hydrogen sulphide,...
5.
6.
Vahdat A, Reiners K, Simhadri V, Eichenauer D, Boll B, Chalaris A, et al.
Leukemia
. 2009 Nov;
24(1):51-7.
PMID: 19890373
Combinations with proteasome inhibitors are currently being investigated to improve the therapy of hematological malignancies. We previously found that proteasome inhibition by bortezomib failed to sensitize anti-CD30 antibody (Ab)-based lymphoma...
7.
Schjoedt K, Hansen H, Tarnow L, Rossing P, Parving H
Diabetologia
. 2008 Apr;
51(6):956-61.
PMID: 18385971
Aims/hypothesis: In type 1 diabetic patients with microalbuminuria not receiving antihypertensive treatment, an increase in urinary AER (UAER) of 6-14%/year and a risk of developing diabetic nephropathy (DN) of 3-30%/year...
8.
Hansen H, Lund S, Rossing P, Tarnow L, Nielsen F, Jensen T, et al.
Scand J Clin Lab Invest
. 2001 Oct;
61(6):471-7.
PMID: 11681537
In type 1 diabetic patients with microalbuminuria not receiving antihypertensive treatment, an increase in urinary albumin excretion rate (AER) of 6% to 14%/year and a risk for the development of...
9.
Parving H, Hommel E, Jensen B, Hansen H
Kidney Int
. 2001 Jun;
60(1):228-34.
PMID: 11422755
Background: The purpose of this study was to assess whether long-term (8 years) inhibition of angiotensin-converting enzyme (ACE) protects kidney function in normotensive type 1 diabetic patients with diabetic nephropathy....
10.
Hansen H, Gaede P, Jensen B, Parving H
Diabetes Care
. 2000 Dec;
23(12):1742-5.
PMID: 11128344
Objective: High-dose treatment with cyclooxygenase inhibitors reduces urinary albumin excretion rate (AER) in type 1 diabetic patients with microalbuminuria and macroalbuminuria. This effect may lead to an incorrect classification of...